The Fellow on Call: The Heme/Onc Podcast Episode 108: Colorectal Cancer Series, Pt. 10 - Metastatic Colorectal Cancer (Part 2)
Jul 17, 2024
Dive into the intricate world of metastatic colorectal cancer with a focus on innovative treatments! Discover the impact of immunotherapy and the promising role of BRAF inhibition. Learn how HER2 targeted therapies, like trastuzumab and tucatinib, are changing the landscape of care for specific patient groups. The discussion also highlights the importance of MMR and MSI testing in tailoring immunotherapy responses, underscoring the trend towards personalized medicine for better outcomes.
AI Snips
Chapters
Transcript
Episode notes
MSI-High Predicts Immunotherapy Success
- MSI-high status in metastatic colorectal cancer predicts good response to immunotherapy.
- Pembrolizumab and combined nivolumab/ipilimumab show durable responses and survival benefits.
Use Combined Immunotherapy First-Line
- Consider ipilimumab plus nivolumab combination for fit patients with metastatic MSI-high colorectal cancer.
- This combo shows improved progression-free survival over chemotherapy in first-line treatment.
Dual BRAF-EGFR Inhibition Needed
- BRAF inhibitor monotherapy in colorectal cancer shows poor responses due to MAP kinase pathway feedback.
- Dual BRAF and EGFR inhibition improves efficacy in BRAF-mutated metastatic colorectal cancer.